Vanguard Group Inc Apellis Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

$5.37 Trillion
Q1 2025

A detailed history of Vanguard Group Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,130,356 shares of APLS stock, worth $240 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,130,356

Previous 10,046,025 0.84%

Holding current value

$240 Million

Previous $321 Million 30.89%

% of portfolio

0.0%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$21.87 - $34.63 $1.84 Million - $2.92 Million	84,331 Added 0.84%	10,130,356 $222 Million
Q4 2024 Feb 11, 2025	BUY	$26.18 - $35.42 $6.03 Million - $8.16 Million	230,450 Added 2.35%	10,046,025 $321 Million
Q3 2024 Nov 13, 2024	BUY	$28.84 - $41.15 $173,703 - $247,846	6,023 Added 0.06%	9,815,575 $283 Million
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $11.6 Million - $18.1 Million	303,686 Added 3.19%	9,809,552 $376 Million
Q1 2024 May 10, 2024	SELL	$55.39 - $72.47 $2.76 Million - $3.61 Million	-49,812 Reduced 0.52%	9,505,866 $559 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $3.18 Million - $5.56 Million	85,701 Added 0.9%	9,555,678 $572 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $1.62 Million - $6.13 Million	68,687 Added 0.73%	9,469,977 $360 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $9.79 Million - $11.9 Million	-127,654 Reduced 1.34%	9,401,290 $856 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $14.7 Million - $21.2 Million	316,453 Added 3.44%	9,528,944 $629 Million
Q4 2022 Feb 10, 2023	BUY	$43.24 - $61.04 $7.84 Million - $11.1 Million	181,412 Added 2.01%	9,212,491 $476 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $13.6 Million - $21.2 Million	304,334 Added 3.49%	9,031,079 $617 Million
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $5.53 Million - $9.33 Million	157,575 Added 1.84%	8,726,745 $395 Million
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $23.1 Million - $35.3 Million	652,071 Added 8.24%	8,569,170 $435 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $35.8 Million - $57.3 Million	1,164,814 Added 17.25%	7,917,099 $374 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $12.8 Million - $28.5 Million	407,829 Added 6.43%	6,752,285 $223 Million
Q2 2021 Aug 13, 2021	BUY	$40.9 - $64.9 $259 Million - $412 Million	6,344,456 New	6,344,456 $401 Million

Others Institutions Holding APLS

# of Institutions

286

Shares Held

125M

Call Options Held

921K

Put Options Held

761K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.61B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Apellis Pharmaceuticals, Inc. Transaction History